Trial Profile
Retreatment With 1st Generation EGFR TKIs in Sensitizing EGFR Mutation Positive Non-Squamous Cell Carcinoma Patients Who Previously Treated With EGFR TKI and Cytotoxic Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Jul 2021 Planned End Date changed from 30 Sep 2022 to 31 Mar 2023.
- 13 Jul 2021 Planned primary completion date changed from 30 Sep 2022 to 31 Mar 2023.
- 13 Jul 2021 Status changed from recruiting to active, no longer recruiting.